The publisher would like to apologise on behalf of the authors. Since publication of the ORIGINAL ARTICLE: CLINICAL in Leukemia & Lymphoma, March 2011; 52(3): 394–399, the authors have informed us of the following error:
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)
C. TOM KOUROUKIS1, LOUIS A. V. FERNANDEZ2, MICHAEL CRUMP3, NEIL SUN CHUA4, RENA BUCKSTEIN5, ROBERT TURNER4, SARIT ASSOULINE6, RICHARD J. KLASA7, WENDY WALSH8, JEAN POWERS8, & ELIZABETH EISENHAUER8
1Juravinski Hospital and Cancer Centre, Hamilton, Ontario, Canada, 2QEII Health Sciences Centre, Halifax, Nova Scotia, Canada, 3University Health Network, Toronto, Ontario, Canada, 4Cross Cancer Institute, Edmonton, Alberta, Canada, 5Odette Cancer Centre, Toronto, Ontario, Canada, 6Jewish General Hospital, Montreal, Quebec, Canada, 7BC Cancer Agency, Vancouver, British Columbia, Canada, and 8NCIC Clinical Trials Group, Kingston, Ontario, Canada
This authorship and affiliation information should have read as follows:
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)
C. TOM KOUROUKIS1, LOUIS A. V. FERNANDEZ2, MICHAEL CRUMP3, RANDY D. GASCOYNE4, NEIL SUN CHUA5, RENA BUCKSTEIN6, ROBERT TURNER5, SARIT ASSOULINE7, RICHARD J. KLASA4, WENDY WALSH8, JEAN POWERS8, & ELIZABETH EISENHAUER8
1Juravinski Hospital and Cancer Centre, Hamilton, Ontario, Canada, 2QEII Health Sciences Centre, Halifax, Nova Scotia,Canada, 3University Health Network, Toronto, Ontario, Canada, 4BC Cancer Agency, Vancouver, British Columbia, Canada, 5Cross Cancer Institute, Edmonton, Alberta, Canada, 6Odette Cancer Centre, Toronto, Ontario, Canada, 7Jewish General Hospital, Montreal, Quebec, Canada, and 8NCIC Clinical Trials Group, Kingston, Ontario, Canada